E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Assessment of the efficacy of interventions to limit ischemic injury by direct measurement of intramural carbon dioxide tension after coronary artery occlusion in the dog.
L. D. Hillis,Shukri F. Khuri,Eugene Braunwald,Robert A. Kloner,D. E. Tow,Ernest M. Barsamian,Peter R. Maroko +6 more
TL;DR: It is concluded that interventions that modify the severity of ischemia can be evaluated by measuring intramural carbon dioxide tension, and that propranolol, hyaluronidase, and nitroglycerin reduce ischemic injury, whereas isoproterenol increases it.
Journal ArticleDOI
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)
Jessica L. Mega,Eugene Braunwald,Stephen D. Wiviott,Sabina A. Murphy,Alexei N. Plotnikov,Nina Gotcheva,Mikhail Ruda,C. Michael Gibson,C. Michael Gibson +8 more
TL;DR: The 2 doses of rivaroxaban reduced cardiovascular events in patients with recent acute coronary syndromes treated with antiplatelet therapies; however, the 2.5-mg dose was associated with lower mortality and fewer bleeding complications than the 5- mg dose, which offers a more favorable balance of efficacy and safety.
Journal ArticleDOI
Mechanochemistry of cardiac muscle: V.Influence of thyroid state on energy utilization
TL;DR: The results suggest that thyroid hormone directly influences the rate of cellular energy utilization and that the calorigenic effects of thyroid hormone may be explained, at least in part, by alterations in the process of energy utilization.
Journal ArticleDOI
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes A Systematic Overview of Randomized Clinical Trials
Pierluigi Tricoci,L. Kristin Newby,Vic Hasselblad,David F. Kong,Robert P. Giugliano,Harvey D. White,Pierre Theroux,Gregg W. Stone,David J. Moliterno,Frans Van de Werf,Paul W. Armstrong,Dorairaj Prabhakaran,Saman Rasoul,Leonardo Bolognese,Eric Durand,Eugene Braunwald,Robert M. Califf,Robert A. Harrington +17 more
TL;DR: In NSTE ACS, treatment with upstream small-molecule GP IIb/IIIa inhibitors provides a significant but modest ischemic benefit when compared with initial placebo, but these modest benefits are associated with an increased risk of bleeding.
Journal ArticleDOI
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial
Alon Eisen,Alon Eisen,Christian T. Ruff,Christian T. Ruff,Eugene Braunwald,Eugene Braunwald,Rose A. Hamershock,Rose A. Hamershock,Basil S. Lewis,Christian Hassager,Tze Fan Chao,Jean-Yves Le Heuzey,Michele Mercuri,Howard Rutman,Elliott M. Antman,Elliott M. Antman,Robert P. Giugliano,Robert P. Giugliano +17 more
TL;DR: The association between digoxin use and worse clinical outcomes highlights the need to examineDigoxin use, particularly when prescribed to control heart rate in patients with atrial fibrillation in a randomized trial.